Dhanushi Rupasinghe1, Jun Yong Choi2, Nagalingeswaran Kumarasamy3, Sanjay Pujari4, Ly Penh Sun5, Tuti Parwati Merati6, Man Po Lee7, Nguyen Van Kinh8, Sasisopin Kiertiburanakul9, Cuong Duy Do10, Anchalee Avihingsanon11, Jeremy Ross12, Awachana Jiamsakul1. 1. The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. 2. Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. 3. CART CRS, Voluntary Health Services, Chennai, India. 4. Institute of Infectious Diseases, Pune, India. 5. National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia. 6. Faculty of Medicine Udayana University & Sanglah Hospital, Bali, Indonesia. 7. Queen Elizabeth Hospital, Hong Kong SAR, Hong Kong. 8. National Hospital for Tropical Diseases, Hanoi, Vietnam. 9. Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 10. Bach Mai Hospital, Hanoi, Vietnam. 11. HIV-NAT/ Thai Red Cross AIDS Research Centre and Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 12. TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand.
Abstract
BACKGROUND: Although the prevalence and mortality of hepatitis is high in the Asia-Pacific region, few studies are available on the diagnosis, treatment, and cure rates for viral hepatitis among people living with HIV in this area. This study aims to report the cascade of care (CoC) for hepatitis B (HBV) and C (HCV) among people living with HIV receiving combined antiretroviral therapy (ART). METHODS: Patients enrolled in the TREAT Asia HIV Observational Database Low Intensity Transfer (TAHOD-LITE) cohort, on ART, and with follow-up data from 2010 to 2019 were included. Patients were determined as positive for HCV or HBV co-infection if they ever tested positive for HCV antibody (anti-HCV) or HBV surface antigen (HBsAg), respectively. RESULTS: In total, 39% (8612/22 340) of the adult HIV cohort had undergone HBsAg testing, with 8% (672/8612) testing positive. HBV CoC demonstrated that 71% (474/672) of those with HBsAg positive results initiated treatment, 67% (318/474) of those on treatment had HBV DNA testing to evaluate treatment progression, and 18% (58/318) of those tested reached viral suppression. Of the cohort, 37% (8231/22 340) had anti-HCV testing, of whom 10% (779/8231) tested positive. The HCV CoC showed that 68% (526/779) of those with positive anti-HCV tests had HCV RNA tests, of whom 51% (267/526) had detectable HCV RNA. Among those with detectable HCV RNA, 65% (174/267) initiated HCV treatment. Of the 40% (69/174) who initiated HCV treatment, 90% (62/69) reached sustained virological response. CONCLUSION: Our findings identified less frequent testing in the healthcare system and limited access to treatment as gaps in the CoC for viral hepatitis. More routine HCV RNA and HBV DNA testing is required for patients with positive screening tests to identify those in need of treatment.
BACKGROUND: Although the prevalence and mortality of hepatitis is high in the Asia-Pacific region, few studies are available on the diagnosis, treatment, and cure rates for viral hepatitis among people living with HIV in this area. This study aims to report the cascade of care (CoC) for hepatitis B (HBV) and C (HCV) among people living with HIV receiving combined antiretroviral therapy (ART). METHODS: Patients enrolled in the TREAT Asia HIV Observational Database Low Intensity Transfer (TAHOD-LITE) cohort, on ART, and with follow-up data from 2010 to 2019 were included. Patients were determined as positive for HCV or HBV co-infection if they ever tested positive for HCV antibody (anti-HCV) or HBV surface antigen (HBsAg), respectively. RESULTS: In total, 39% (8612/22 340) of the adult HIV cohort had undergone HBsAg testing, with 8% (672/8612) testing positive. HBV CoC demonstrated that 71% (474/672) of those with HBsAg positive results initiated treatment, 67% (318/474) of those on treatment had HBV DNA testing to evaluate treatment progression, and 18% (58/318) of those tested reached viral suppression. Of the cohort, 37% (8231/22 340) had anti-HCV testing, of whom 10% (779/8231) tested positive. The HCV CoC showed that 68% (526/779) of those with positive anti-HCV tests had HCV RNA tests, of whom 51% (267/526) had detectable HCV RNA. Among those with detectable HCV RNA, 65% (174/267) initiated HCV treatment. Of the 40% (69/174) who initiated HCV treatment, 90% (62/69) reached sustained virological response. CONCLUSION: Our findings identified less frequent testing in the healthcare system and limited access to treatment as gaps in the CoC for viral hepatitis. More routine HCV RNA and HBV DNA testing is required for patients with positive screening tests to identify those in need of treatment.
Authors: David Tordrup; Yvan Hutin; Karin Stenberg; Jeremy A Lauer; David W Hutton; Mehlika Toy; Nick Scott; Marc Bulterys; Andrew Ball; Gottfried Hirnschall Journal: Lancet Glob Health Date: 2019-07-25 Impact factor: 26.763
Authors: Nicole L De La Mata; Nagalingeswaran Kumarasamy; Vohith Khol; Oon Tek Ng; Kinh Van Nguyen; Tuti Parwati Merati; Thuy Thanh Pham; Man Po Lee; Nicolas Durier; Matthew Law Journal: Antivir Ther Date: 2016-02-10
Authors: S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao Journal: Hepatol Int Date: 2015-11-13 Impact factor: 6.047
Authors: Yun-Chi Chen; Chloe L Thio; Andrea L Cox; Sebastian Ruhs; Farin Kamangar; Kjell J Wiberg Journal: BMJ Open Date: 2019-03-30 Impact factor: 2.692